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ABSTRACT
Alexander Emanuel Velázquez: CORONARY ARTERY DISEASE: AN ANALYSIS OF ITS
BIOCHEMICAL, PHYSIOLOGICAL, AND SOCIOLOGICAL CAUSES AND EFFECTS

Coronary Artery Disease (CAD) is a serious condition caused by a buildup of plaque in your
coronary arteries, the blood vessels that bring oxygen-rich blood to your heart. It
disproportionately affects millions of Americans and thousands of Mississippians. This study
presents the results of an evaluation of causation factors of CAD, the physiological impact on the
body, and the contributing determinants of CAD on Mississippi populations. Data on Mississippi
populations were collected using the Center for Population Studies at the University of Mississippi.
A multitude of individuals were evaluated when examining the causes and effects of CAD
including men, women, children, and the elderly. The evaluation processes and procedures of all
facets of CAD are given in great detail, so that this paper depicts the evolution of the evaluation,
including changes in methodologies and treatment instruments in dealing with CAD. The findings
of this research reflect the challenges faced by providers / public health officials in dealing with
CAD in Mississippi. Findings for each of the aforementioned results are presented along with a
discussion of what changes have been made or not made to aid the issue and why. While the
findings of CAD’s effect on Mississippi populations is not generally quite positive, the
improvement in the detrimental effects of CAD in recent years clearly allows the possibility of
removing the disease as an issue in our state.
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CHAPTER 1
ATHEROGENESIS
Within this chapter I hope to explain the meaning of what occurs on a cellular level within
the body during Coronary Artery Disease. The causes, effects, and what happens elsewhere in the
body will be explained here. Coronary Artery Disease does not occur overnight. The severity of
the disease as it unfolds will be discussed in this chapter. First, I need to defined the relevant
vascular structure that is in play as the disease develops. Next, I will develop the story of the
inflammatory processes and pathology of the disease, and then the immediate macroscopic
manifestations of coronary artery disease in health.
DEFINITION OF CORONARY ARTERY DISEASE
A coronary artery is a blood vessel that feeds the heart, a muscle that must run aerobically
in order to have the ATP to ensure its continued contraction. Coronary Artery Disease (CAD) is
damage or disease in the heart's major blood vessels. The usual cause is the buildup of “plaque,”
a colloquialism that is convenient to use and will be used throughout this document, but will be
defined properly below. Plaque buildup causes coronary arteries to narrow, limiting blood flow to
the heart. Coronary artery disease can range from no symptoms, to chest pain (angina), to shortness
of breath, to fatigue and nausea, to a heart attack. A heart attack, also called a myocardial
infarction, occurs when the flow of blood to the heart is blocked restricted to the point that the high
demand for oxygen cannot be met by the restricted blood flow, and the heart muscle cannot
continue to contract in locally or globally. Plaques are most often due to a buildup of fat,
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cholesterol and other substances. Plaque can weaken the vascular wall and lead to additional
problems as discussed below.1
In order to begin the discussion of the formation of plaques, called atherogenesis, we must
first review the structure of vascular tissue. Coronary arteries are much more than just pipes for
blood flow to feed the heart muscle, they have multiple layers with different properties and
purposes. Blood vessels are lined with Endothelial cells, a sheet of cells similar to epithelial cells,
but generally more permeable to small solutes and water. There are various tissues connected to
the heart that are involved in this buildup of plaque, and these tissues range from the tunica, intima,
and endothelium.1

Figure 1: Definitions of key players
(A) Artery Structure. From the center out: Tunica interna or “Intima” comprised of the
endothelium, a subendothelium and a layer of connective tissue (elastic lamina), Tunica Media
comprised of the smooth muscle layer and another layer of connective tissue (elastic lamina).
Figure from https://en.wikipedia.org/wiki/Artery.

(B) Illustration of coronary arteries and Plaque inside a coronary artery.
Coronary arteries feed the heart muscle itself. Thus, blockage of a coronary artery means that
the heart muscle is oxygen starved. Illustration of a plaque in a coronary artery.
Figure taken from https://www.wnyurology.com/content.aspx?chunkiid=11986 (Copyright © Nucleus
Medical Media, Inc.).
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TISSUE BIOLOGY OF ATHEROGENESIS
Coronary Artery Disease is not only a cholesterol storage disease, it is now known to be a
complex interaction of risk factors including cells of the artery wall and the blood, and molecular
messages that they exchange. While the accumulation of plaque within these arteries can couple
with a variety of physiological effects (Chapter 3), for now, we will focus on the very local events
in the coronary artery itself. There is a plaque, and the possibility for the formation of a blood clot
that forms due to tissue remodeling and weakening, and the amplification of the problem because
of these two coupled events. As described below, there is due to a complex interplay between clot
formation and recruitment of immune cells and plaque formation.
This story begins with a diet that is atherogenic.2 Specifically, this term refers to the
tendency of a diet that will lead to the persistence of a particular form of Low Density Lipoproteins
in the blood that are depleted of most of their Triglyceride cargo, slow to clear from the blood
plasma, have abnormal association of immune cells with the arterial wall, and are particularly
sensitive to oxidative stress.3 In studies of rabbits that are fed an atherogenic diet, the expression
of vascular cell adhesion molecule-1 (VCAM-1) is up regulated in the arterial endothelial cells.4
Subsequently, interactions between monocytes, a leukocyte present in the blood, adhere to VCAM1 and migrate into the intima, the innermost section of the artery or vein. This process begins
within 12 days of the start of a high lipid diet in eukaryotic cells with association and migration of
cells (Figure 2A).
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Figure 2. Participation of inflammation in all stages of atherosclerosis.5
(A) When cardiac endothelium becomes inflamed, it expresses VCAM-1 that binds monocytes from the
blood. Monocytes transform to fat filled macrophages causing stenosis of the cardiac artery. Macrophages
differentiate into dendritic cells.6
(B) T lymphocytes are recruited to the dendritic cells further add to the secretion of cytokines and growth
factors that promote remodeling smooth muscle cells (SMCs) and the elastin and collagen network. of the
migration and proliferation of SMCs. Medial SMCs express specialized enzymes that can degrade the
elastin and collagen in response to inflammatory stimulation.7
(C) Ultimately, inflammatory mediators can inhibit collagen synthesis and evoke the expression of
collagenases by foam cells within the intimal lesion. Thus, when the plaque ruptures, as shown here, the
tissue factor induced by the inflammatory signaling triggers the thrombus that causes most acute
complications of atherosclerosis.

Within 12 weeks of this process, foam cells within the intima are shown to form the “fatty
streaks” that are precursors to plaque, and the very monocytes, now called macrophages, that are
the cell that are the “foam” cell. Transmigration of the leukocytes typically is dependent on the
expression of chemoattractant cytokines regulated by signals that are associated with traditional
and new risk factors for CAD. Once they arrive at the arterial intima, the leukocytes present, which
are mainly mononuclear phagocytes and T lymphocytes, communicate with smooth muscle cells
(SMCs) and the endothelium; these are the cells that are endogenous to the arterial wall (Figure
2B).
4

The presence of large aggregates of lipid filled macrophages then became associated with
focal defects in the endothelial lining that exposed collagen, and in some models, platelet adhesion
was seen in such areas (Figure 2C). Due to the inflammatory ferment that occurs in early
atherogenesis, SMCs move away from the tunica media, the middle layer of and within the intima.
These cells then undergo proliferation and form a thick extracellular matrix. In conjunction with
endothelial cells and monocytes, the SMCs secrete matrix metalloproteinases (MMPs) that
respond to the various oxidative, inflammatory, and autoimmune signals received. MMPs are in
balance with their endogenous tissue inhibitors, and they moderate various functions of vascular
cells that include activation, proliferation, migration, and cell death. More importantly, they can
moderate new vessel formation, geometric remodeling, healing, or destruction of extracellular
matrices of arteries and the myocardium.8
A recent review by Bäck, et al (2019) provides cellular level insight into observations made
two decades earlier. Libby, et al noted that the appearance of the fat streaks was associated with
an increase in the adhesion of monocytes to the endothelial surface, suggesting that lipid filled
macrophages have a dynamic relationship with the intima.5 Figure 3 below illustrates indeed there
is an active dynamic between LDL and the cell surface which would be directly reflected in the
nature and fate of the “foam” cell, i.e. lipid filled macrophages.9 Macrophages have a range of
phenotypes that range from very pro-inflammatory to anti-inflammatory. As discussed above
macrophages envelop LDL leading to transdifferentiation into a foam cell (center of Figure 3).
SMCs also form foam cells (left side of Figure 3) like the macrophages do and there is evidence
that both of these cells can migrate back out of the intima- anti-inflammatory macrophages
carrying the inflammatory lipids out of the tissue. If the load of transdifferentiated SMC and
macrophages is high, then they release pro-inflammatory chemicals into the now inflamed intima.
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This leads to further decline, and apoptotic cells creating a necrotic core of lipid waste in the intima
that is to become the “plaque” of concern here. The plaque itself is responsible for secreting proinflammatory cytokines.9

Figure 3. Macrophage life cycle and cholesterol round trip in atherosclerosis.9
The central portion of the figure shows the penetration of monocytes and their transformation to
macrophages in the intima layer. The more pro-inflammatory signals that are in the tissue, the more
monocyte penetration and transformation. On the left, cholesterol from LDL accumulates and is taken up
and transforms both macrophages and smooth muscle cells thereby creating “foam” cell versions of each.
Pro-inflammatory factors trigger apoptosis, and the lipid “plaque” forms at the necrotic core of the intima
layer.

Proteoglycans in the extracellular matrix bind lipoproteins and prolong their occupation of
the intima, thus making them more susceptible to oxidative stress and glycation. These products
6

of lipoprotein modification, including oxidized phospholipids and glycation end products, receive
and spread the inflammatory response. As the lesion enlarges, calcification can then happen
through processes similar to those in bone formation. Along with proliferation, cell death
frequently occurs alongside within the atherosclerotic lesion that occur when accumulations of
lipid, cells, and matrix components, including minerals, are associated with structural
disorganization, repair, and thickening of the intima, as well as deformity of the arterial wall. The
death of lipid-full macrophages leads to extracellular deposition of tissue factor (TF). The
extracellular lipid that gathers within the intima can accumulate and create the lipid-rich “necrotic”
core of the atherosclerotic plaque which will then go onto form the plaque that fills the arteries
within our hearts.8

FROM A MACROSCOPIC VIEW
While death and other health complications of CAD are due to cardiac arrest, not all of
these complications are cardiovascular in origin. The heart can be damaged as a result of
respiratory failure or cerebral failure. Therefore, death can be defined as cerebral, respiratory, or
cardiovascular issues.
In a cerebral setting, cardiac arrest occurs in the setting of brain apoplexy which is an effect
of a hypertensive hemorrhage. This hemorrhage can occur in the acute cerebral edema, where
cardiorespiratory centers are located, and lead to a tragic loss of autonomous central respiratory
functions. The heart will then begin to stop and cardiac arrest will commence. Sudden death can
occur during epileptic seizures that are associated with respiratory chest muscle paralysis. Within
patients diagnosed with epilepsy, there is a 20-fold increased risk of sudden death compared to
those with the same risk factors who are not diagnosed with epilepsy.
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In a respiratory setting, a simple airway obstruction can occur and lead to an acute failure
of ventilation and alveolar gas exchange, which produces hypoxia and final heart failure. This is
an example of the “chest pain” commonly associated with the onset of heart failure. Within the
walls of the bronchitis, eosinophil release by inflammatory cells can jeopardize function due the
thickening of the bronchial walls. In situations where patients undergo unconsciousness, this
occurs during airway obstruction where ventilatory function is endangered, but circulation and
brain function is preserved during the attack.
Finally, in a cardiovascular setting is where plaque can have such an immediate effect on
health. Plaque forming within the aorta or pulmonary artery can impede blood flow. Plaque
residing within any one of the major cardiac structures, whose integrity is critical for regular heart
function, is critical not only in blood flow but for maintenance of electric impulse propagation
during regular pace-making functions. A dysfunction of any of these structures that is sudden can
lead to the instantaneous death that is seen during severe heart attacks or strokes. Overall, over
50% of coronary heart disease is attributed to cardiovascular mechanisms due to plaque
accumulation that leads to sudden death.10
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CHAPTER 2
POPULATION STUDIES
In this section of the thesis, I will explore the topic of the footprint of general health,
lifestyle and access to healthcare correlate with the occurrence of coronary artery disease in
residents of the state of Mississippi. The information in this section is statistical in nature, but
paints a clear picture of the challenges our state faces. Every year an average of 1,700 people in
Mississippi die from coronary heart disease. In 2016, CAD was the sixth highest cause of death in
Mississippi, accounting for approximately 5.4% of all deaths. Unfortunately, the death rate due to
coronary heart disease in 2016 was 1.4 times higher than that of the national rate, and it
disproportionately affected African Americans and men. In 2000, Mississippi had the sixth highest
age-adjusted stroke death rate in the United States, and in 2016, the second highest rate (Figure 4).

Figure 4: American Heart
Association Fact Sheet for the
state of Mississippi: 2010 fact
sheet.
Notice that in 2010 the state of
Mississippi was FIRST in the
nation
for
deaths
from
cardiovascular disease!
(From
https://www.heart.org/idc/groups/heartpublic/@wcm/@adv/documents/downlo
adable/ucm_307186.pdf)
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Trends in MS
Assessing trends in stroke deaths by race and sex would provide important information for
community and population health program managers, policy makers, advocacy organizations, and
health professionals as they seek to spread stroke awareness, prevention, and treatment programs
that address stroke disparities in Mississippi. There are few studies that have examined annual
changes in stroke death rates in Mississippi. To address this gap, researchers with the American
Heart Association calculated the annual percentage change (APC, trend segment) and the average
annual percentage change (AAPC) in age-adjusted stroke death rates among Mississippi adults
aged 35 or older from 2000 to 2016. In addition, they examined differences in the AAPC by age,
sex, and race. Below are listed some of the risk factors within Mississippi residents.

TABLE 1: Heart Disease and Stroke Risk Factors in Mississippi
Individuals

MS

US

Adults who are current smokers

26%

21.1%

Adults who participate in more than 50 min of aerobic physical 40%
activity per week
Adults who are overweight or obese
68.9%

51.5%

Adults who have been told they have had a heart attack

5.4%

4.4%

Adults who have been told they have had a stroke

4%

2.9%

Adults who have been told they have angina or CHD

4.6%

4.1%

Population of adults (16-64) who have health care coverage

69.3%

78.9%

High School students who are obese

15.8%

13%

63.5%

(From https://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_307186.pdf)
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Prevention Plans
To affect the burden of heart disease and stroke in Mississippi, programs implemented must
reduce the incidence of preventable risk factors: Physical Inactivity, Poor Nutrition, and Tobacco
Use. Currently, 84 percent of the adult population has one or more of these risk factors.
Additionally, 2.8 percent have the “deadly quartet”: high blood pressure, high cholesterol,
diabetes, and obesity. Lawmakers in Mississippi have created plans to address these risk factors in
a two-fold approach: prevention of potential risk factors and management of existing risk factors.
Risk factors addressed with the prevention approach include the lack of regular physical activity,
improper nutrition, and tobacco use. Increasing physical activity and proper nutrition can prevent
many of the other risk factors such as obesity, diabetes, high blood pressure, and high blood
cholesterol. Reducing tobacco use will also contribute to reducing high blood pressure and high
cholesterol. The second approach is to manage existing risk factors. While the hope is to prevent
cardiovascular disease through lifestyle changes, programs and interventions must be developed
to deal with the population that does acquire these risk factors. These risk factors include
hypertension, obesity, abnormal cholesterol, and diabetes. The plan also discusses socio-cultural
factors that influence cardiovascular health. For each risk factor the Plan created includes 10-year
objectives to achieve the stated goals and addresses specific actions needed in the community
environment, worksites, and healthcare settings. For each setting, the Plan develops strategies
based on collaborations/partnerships, program services, public awareness, and policies. The Plan
discusses implementation of the strategies and evaluation in later sections.
Physical Inactivity
Regular physical activity is associated with a healthier, longer life. Physically active people
have a lower risk of heart disease, high blood pressure, diabetes, obesity, and some types of cancer
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than less active people. Therefore, a need exists for effective population-based interventions to
promote increased physical activity. Although intensive physical activity is recommended for
cardiorespiratory fitness, even moderate levels of physical activity can have significant health
benefits.11 Physical activity does not need to be strenuous to achieve health benefits; people who
are inactive can improve their health and well-being by becoming even moderately active on a
regular basis. Even greater health benefits can be achieved by increasing the amount (duration,
frequency, or intensity) of physical activity.12. Physically inactive people are almost twice as likely
to develop CHD as people who engage in regular physical activity. The CHD risk from physical
inactivity is almost as high as that from cigarette smoking, high blood pressure, and high
cholesterol; and physical inactivity is more prevalent than any of these other risk factors.11, 13
Table 2: Physical Inactivity13
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Improper Nutrition
Optimal nutrition can help lower the risk of developing chronic diseases and their risk
factors. High fat, high sugar, and low nutrient foods are quick, plentiful, inexpensive, and widely
available. However, healthy eating is often perceived as being time-consuming, expensive,
complicated, and/or unappealing. The trend for increasing portion sizes in restaurants continues,
particularly in fast food and convenience stores where high fat foods and high sugar beverages are
common. Larger sizes are heavily promoted in advertising and at point of sale. In many cases,
these large portions far exceed recommendations of the USDA and FDA. Research shows that
Americans are eating too much food with little nutritional value. High fat, high sodium, high sugar
foods are even served in schools on a regular basis. More than 84 percent of children and
adolescents eat too much fat and 51 percent eat less than one serving of fruit per day. Appropriate
nutrition is one of the easiest ways to reduce key risk factors for cardiovascular disease such as
high blood pressure, high cholesterol, obesity, and diabetes. Population-based strategies must be
implemented to address access to food with high nutritional value, to educate the public on the
necessity of consuming such foods, and to provide incentives to choose healthier alternatives.13
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Table 3: Improper Nutrition13

Tobacco Use
Tobacco use, in particular smoking, still remains the primary cause of preventable disease
and death in the United States and in Mississippi. Since the year 2000, more than one million
young teenage people have been introduced to or become regular smokers, and upwards of 400,000
adults die from tobacco-related diseases in the United States. Tobacco dependence is primarily
viewed as a chronic disease with waves of remission and relapse.14 Tobacco use throughout the
nation has resulted in more than $50 billion annually in direct medical costs. Tobacco smoking
kills more people each year than the AIDS virus, alcohol consumption, prescription drug abuse,
car crashes, murders, suicides, and fires all combined with each other. Approximately 80 percent
of adult smokers started smoking before the age of 18, and every day, nearly 3,000 young people
under this age become regular smokers. More than five million children living today will die
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prematurely because of a decision they will make as adolescents – the decision to smoke cigarettes.
In addition to tobacco use, environmental tobacco smoke (ETS) exposure remains the third leading
cause of preventable death in the United States today. Most state and local laws for clean indoor
air reduce but do not eliminate nonsmokers’ exposure to ETS.14 What was the enabler for these
terrible statistics? Our past governor was a wealthy man because he was a lobbyist for the tobacco
industry. With the settlement from the lawsuit against the tobacco industry every state got money
for smoking cessation programs. Our state initiated these programs, but then gutted them and used
the money for something else- like for the school system.
Even with all these astonishing facts, there is evidence that tobacco use in this nation can
be reduced through existing types of interventions, in line with health objectives detailed in
Healthy People 2010.15 Treating tobacco dependence is particularly important economically, as
treatment can prevent a variety of costly chronic diseases, including heart disease, cancer, and
chronic lung disease. It has been estimated that smoking cessation is more cost-effective than other
commonly provided clinical preventive services, including screening for cervical, breast, and
colon cancer; treatment of mild to moderate high blood pressure; and treatment of high.14 Most
smokers become addicted at a young age. In fact, 90 percent of those killed by tobacco started
smoking before the age of 18. Therefore, preventing young people from using tobacco will help
them to live longer, healthier lives.16 Even for nonsmokers, reduced smoking rates mean a better
quality of life. Every year, Mississippi taxpayers foot the bill for an estimated $320 million tax
burden due to tobacco related healthcare costs.13, 16
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Table 4: Tobacco Use13

As time has progressed, the success rate of this plan has become apparent. Within a 2017
study performed by Jackson State University, the development of high blood pressure and obesity
among African American Adolescents in Mississippi was explored. Childhood obesity has reached
epidemic proportions and is linked to hypertension among African American youth in Mississippi.
There is an apparent optimistic bias that influences behavior of youth causing them to
underestimate their susceptibility to negative health outcomes. The study explored adolescent
behaviors and prevalence of high blood pressure and obesity in a school district. The researchers
examined the relationship between individual health risk practices and optimistic bias on health
outcomes; 433 African American high school students were administered a survey and had their
obesity and blood pressure measured by the school nurse. Canonical correlational analyses were
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used to examine relationships between health risk practices and descriptive statistics for optimistic
bias and health outcomes. Engaging in moderate exercise for at least 30 min in the last 7 days and
lower blood pressure was the only statistically significant relationship. Two-thirds of the students
did not perceive themselves to be at risk of developing cardiovascular disease with males at greater
risk than females, despite the presence of clinical risk factors for hypertension and obesity.
Reducing health optimistic bias is an effective way of motivating young people to adopt more
positive behaviors using educational institutions to implement intervention programs that promote
positive health behavior as a way to reduce health disparities. The cornerstone of cardiovascular
health prevention and risk reduction in children and adolescents is characterized by a combination
of lifestyle change and the adaptation of healthy behaviors that can become a major component of
the education system curriculum. This is an important first step in the fight to reduce health
disparities and health risks that plague many communities around America, and the State of
Mississippi. As adult obesity and childhood obesity continue to escalate in Mississippi, education
and awareness of the effects of the risk factors are important strategies that would motivate changes
in behavior. Some researchers have stressed that inaccurate self-diagnosis can be a predictor of
morbidity and mortality. So, it is important for communities to implement strategies that increase
the potential for change in health status by implementing targeted person-environment public
health interventions to ensure, not only accurate assessment of health status, but also the
development of adequate prevention and intervention strategies.
Despite the overwhelming causative agents that are prevalent in Mississippi, how can we
as a state improve in helping those already afflicted by heart disease? As previously mentioned,
the population of Mississippians who currently own health insurance is 69%, currently 10% below
the national average. The inability to pay for medical care could potentially lead to the disparities
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across the board that are present in those afflicted by heart disease. As of July 2012, approximately
one-third of the entire Mississippi population is classified as “underserved” by primary medical
care. Primarily, there is a disparity across the state when it comes to the amount of primary care
physicians with Mississippi ranking 48th in the nation. Despite gains to provide sufficient access
to primary care, the lack of managed care options and lack of systematic integration amongst
physicians, hospitals, and insurers.
Another issue is Mississippi’s high rate of limited access to primary health care than people
covered by private insurance or Medicare. However, access to health care does not equal access to
primary care. An example of this is the inability to gain access to an appointment with a physician.
The option of scheduling an appointment with physician extenders (nurse practitioners, physician
assistants, registered nurses) or wait an extended period to see a primary care physician was rarely
offered in a 2014 survey.17 The survey results showed that consumers would gladly see a nurse
practitioner or physician assistant, and research shows that nurse practitioners could be used to
reduce the national shortage of primary care providers.18 Future research should explain the
geographic differences in access to primary health care in relation to rural vs. urban areas in
Mississippi.
To put it simply, I would like to point out that the state's plan must address the structural
realities that constrain health behaviors as discussed in the Kaiser website's page. In other words,
it's great to integrate healthy eating and cooking education in public schools; but if you live in
Marks, MS, you have no grocery store to buy healthy food. Also, it's great to encourage people to
take a walk, but if their neighborhood has no sidewalks or is dangerous, people are not going to
want to take exercise outside. While access to health does determine health, Social determinants
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of health also include factors like socioeconomic status, education, neighborhood and physical
environment, employment, and social support networks.19
In conclusion, Mississippians, who are some of the poorest and sickest Americans, have a
lack of regular access to primary care that is concerning, especially since new research has been
found that an expansion of Medicaid eligibility is associated with a significant decrease in
mortality rates, emergency department visits, and the burden of cost.17, 20
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CHAPTER 3
GENETICS VS LIFESTYLE.
When observing what is the true causative agent of Coronary Artery Disease, there is no
one true observable obstacle. The multitude of diseases that occur can be the effects of a lifetime
of poor decisions, or they can be a result of a defection that was present at birth. While both play
an important role in the formation of the disease, the majority of time is spent on lifestyle habits
due to the fact that this is the most preventable cause of disease. However, I hope to show that
both Genetics and Lifestyle can be causative agents in this disease.
Genetic Linkage Analysis
In order to ascertain a particular specific gene with a particular cardiovascular disease,
researchers primarily use linkage analysis and association studies. Linkage analysis has shown
great levels of success in disease with simple, Mendelian patterns of inheritance that have a
singular gene that displays tremendous phenotypic effect. The causal genetic mutation that can be
ascertained using DNA sequencing that we are particularly interested is the Low-density
lipoprotein receptor gene mutation (an exon deletion) that causes homozygous familial coronary
artery disease. Researchers were able to find a correlation between the two, but even with the
apparent genotype-to-phenotype linkage, there was not always a simple one-to-one correlation.
Pleiotropy is the production by a single gene of two or more apparently unrelated effects, and can
be observed by mutations in different sites on the same gene or distinct mutation at the same site
leading to different outcomes. For example, one individual in a pedigree may exhibit cardiac
arrhythmia, whereas another individual with the same disorder in either the same or different
pedigree shows muscle weakness and deafness. Penetrance is the proportion of genotype carriers
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who actually express a particular phenotype. For example, if a mutation in the gene responsible
for a particular autosomal dominant disorder has 95% penetrance, then 95% of those with the
mutation will develop the disease, while 5% will not. These two variabilities in expression can be
the result of environmental factors or other “modifier genes” that are not identified by simple
linkage analysis trials. Because of this, researchers have undertaken the role of association studies
in order to find genetic causation for traits not obeying Mendelian Genetics. Some common genetic
mutations that occur in patients with CAD are the mutations in low-density lipoprotein receptor
by exon deletion causing homozygous familial hypercholesterolemia, missense mutations in 𝛃Myosin heavy chain (MYH7) that cause left-side lesions at birth, and nonsense mutations in
transcription factor TBX that cause cardiac malformation.10
Genome-wide Association Studies:
Genome-wide association studies (GWAS) have been the principal approach when
identifying the genetic causations for traits with intricate inheritance patterns-traits that involve
multiple genes that can potentially interact with environmental factors. As previously mentioned,
clinical numbers such as lipid levels can occasionally have single Mendelian mutations that cause
significant phenotypic effects. However, the majority of clinical values such as hypertension are
influenced by multiple interacting genes with variant frequencies. While the trait itself will display
Mendelian inheritance (as ascertained by a simple Punnett Square), the overall particular trait
represents a nonlinear relationship of numerous different inputs, and therefore can be impacted by
external factors. For the example of cholesterol levels, genetic variation in apoprotein synthesis
and degradation, LDL internalization and processing, gastrointestinal lipid uptake, and receptor
synthesis and degradation will all impact the ultimate levels, and especially diet.
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Figure 5: An illustration of a Manhattan plot depicting several strongly associated risk loci for
mutations in the MYH7 gene on Chromosome 20. Each dot represents a single-nucleotide
polymorphism which is when is a DNA sequence variation occurring when a single nucleotide in
the genome (or other shared sequence) differs between members of a species or paired
chromosomes in an individual, with the X-axis showing genomic location and Y-axis showing
association level, or the relationship between a phenotype and a single-nucleotide
polymorphism.21
Current Available Testing
In previous years before the current genetic understanding, there were a small number of
well-defined instances where genetic testing was indicated, and most practitioners would approach
these with confidence. In today’s world, genetic etiologies are as common as infections in
differential diagnoses, and the complexity of analyzing results can be overwhelming. The first step
is identifying a few key conditions as a clinician. The basic clue for a genetic etiology is the
presence of family history of heart disease. An individual with a family with multiple related
individuals being affected by heart disease, even if barely different in clinical appearances,
supports an underlying genetic relationship. However, in a typical clinical setting genetic factors
can be too complex to warrant genetic testing. This leads to the “grey area” that physicians must
deal with when giving consideration to such presentations to determine if a diagnosable genetic
condition exists. What makes this issue difficult is the idea of variable expressivity, or the degree
to which a phenotype is expressed by individuals having a particular genotype. For example, in
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2012 a Jackson, MS family was affected by congenital dilated cardiomyopathy. However, the
individuals were diagnosed with a mix of severe heart failure, sudden cardiac death, and
arrhythmia. By this same logic it can be assumed that some of the healthy individuals may have
had the variant but never shown signs of the disease. Finally, the last major contributing factor as
to why genetics can be difficult to research when studying family histories of CAD is that many
of the mutations causing cardiovascular disease in affected individuals typically occur de novo.
Lifestyle: Gene–environment interaction
What effect can the physical environment have on the chemistry of our body? From the
time we are born, we are given the genome that we have, but aside from natural mutations how
can this genome change and develop into the genome that causes this disease? Nature vs nurture
is the question here, and the answer is that both matter when determining Gene-environment
interaction. Gene-environment interaction implies that in combination the effect of the genotype
and the environmental factor under study deviates from the additive effects of the factors.
Environmental risk factors
There are various, distinct environmental variables that have the ability to influence lipid
levels and increase the risk of CHD. These variables mainly include dietary fat, smoking, alcohol
consumption, and lack of exercise. The problem researchers face in determining which of this is a
causative factor is that quantifying these with any precision is incredibly difficult.22 Questionnaires
are used to determine most of the environmental factors, but activities such as smoking or alcohol
consumption might be under-reported and activities such as exercise perhaps be over-reported.
Also, variables such as tar content are limiting factors in determining the impact of cigarette/ecigarette smoking. With things such as food consumption, daily food records of patients might be
useful, but understanding the fat content and fatty acid composition of food is not as simple. What
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would be most useful are biomarkers for environmental factors such as plasma measurements of
by-products that can be numerically quantified. Examples of this include plasma cotinine, the
major metabolite of nicotine, to measure cigarette consumption or levels of plasma linoleic acid
as a measure of dietary compliance to dietary guidelines.
The model for the relationship between genetics and environmental factors is shown in
Figure 6. In the general population there is a variety of genetic risk profiles, with each person
having a position along the risk spectrum varying from low to high genetic risk. Related individuals
can position themselves differently on the environmental spectrum of risk by the differing lifestyle choices they make. The important thing to remember is that the environmental risk factors
are modifiable while the genetic risk factors are, unfortunately, not. Genomic environment
interaction is important only when an individual with a high-risk genetic profile inhabits a highrisk environment. Only then will the effect on risk be so grand that premature CHD can occur and
develop.
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Figure 6. Model for gene–environment interaction.22
This model proposes that each individual occupies a position on the genetic risk spectrum,
depending upon how many risk-increasing gene variants have been inherited. Similarly,
individuals are exposed to a range of environmental challenges depending on life-style choices.
This theory proposes that risk of CHD only occurs when an individual at high genetic risk enters
a high-risk environment, and genetic risks and environment risks alone will not trigger a CHD
event.
Alcohol consumption, alcohol dehydrogenase gene and CHD risk
In order to statistically analyze gene-environment interaction for a quantitative trait that
leads to CAD, such as alcohol dehydrogenase levels, is to use an analysis of covariance with the
genotype and environmental factor entered as main effects and with an interaction term between
the genotypic and environmental factors. An example of context dependency of a genetic variant
on risk of CHD is the example of alcohol dehydrogenase. A common prescription to lower risk for
heart disease in a glass of wine a day, and the way in which the beneficial effect of moderate
alcohol consumption can be modified by variation in the gene for alcohol dehydrogenase.
Moderate alcohol consumption has shown to be cardioprotective, thus the saying that “a glass of
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wine a day keeps the cardiologist away.” The risk follows a J-shaped curve, such that individuals
with a low alcohol intake are at greater risk than those who consume moderate amounts of alcohol,
but as alcohol intake increases, the risk of CHD increases. The alcohol dehydrogenase enzyme is
an isoenzyme, which oxidizes ethanol. This enzyme is comprised of 3 subunits, ADH1A, B and
C. Out of all three subunits, genetic variation in ADH1C is the most common and the best studied
of the 3 genes. The ADH1C γ1 allele leads to fast oxidation of ethanol, but the γ2 allele results in
a 2.5-fold slower rate of oxidation. Hines et al.23 showed that in an all-male nested case–control
study drawn from the Physicians Health Study, a moderate consumption of alcohol of about 1
drink/day was correlated with a decreased risk of myocardial infarction. This same study showed
that the ADH1C genotype was also associated with a variation in CHD risk. The question the
researchers then began to ask was ‘does alcohol intake modify the genotypic effects on CHD risk?’.
In the male participants whose alcohol consumption was less than 1drink/week, the researchers
were unable to find an apparent difference in the relative risk of myocardial infarction in γ2 carriers
compared to γ1 homozygous men. The same could not be said for the group who consumed 1 or
more drinks/day. In comparison to γ1γ1 low alcohol consumers, γ1γ1 moderate drinkers had a
higher relative risk, while in γ2γ2 men the relative risk was lower. Therefore, variants in the alleles
of a particular genotype can lead to a different relative risk when it comes to alcohol consumption.
However, in part the risk reduction was defined by a larger increase in high density lipoprotein
levels in γ2γ2 men, and the extent this genotype effect could be estimated by measures of habitual
HDL levels is unclear.
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Discussion
From a macroscopic viewpoint gene–environment interaction has great value because it
shows the reduced risk in never- and ex-smokers and promotes the idea of quitting tobacco
usage. Also, it shows the benefits of moderate alcohol consumption with a particular benefit in a
genotype-specific manner. Therefore, the study of gene–environment interaction not only shows
a meaningful way to improve our understanding of disease pathology at the molecular level, but
also allows specific targeting of advice and therapies to high-risk subjects (those with a high-risk
genotype in a high-risk environment).
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CHAPTER 4
ANOMALIES OF CORONARY ARTERY DISEASE
What makes CAD such a special disease? While we have examined the causes, detriments,
and effects on the population that it might have, there still persists a need for such continuous CAD
prevention, and research. The volatility of the causes, effects, and prevention methods are what
make this disease so peculiar than other diseases. Overall, it is the effect that the disease can have
on the entire body. Even King Solomon cited the heart as “the wellspring of life” and while others
might argue that organs such as the brain or liver are more important, the heart is the “motor of the
ship” that is the human body. In this section I hope to outline the potential anomalies that Coronary
Artery Disease can present to the entirety of the body, despite being a disease that is correlated
with the heart.
Depression and Coronary Artery Disease
Depression is considered to be a mental health disorder characterized by a disinterest in
daily life and activities. It is typically correlated with an imbalance of neurotransmitters in the
synapses of the brain. However, depression is a common illness displayed by patients with
coronary heart disease, and these patients display risk factors for cardiac morbidity and mortality.24
How could an illness correlated with the nervous system be impacted with a degeneration of the
cardiovascular system?
Depression is an illness associated with dysfunction in the autonomic nervous system; this
in part might explain the increased risk factors in patients. Heart rate variability reflects how often
the rhythm of the heart beats will change. Low heart rate variability typically occurs during
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anaerobic exercise, psychological events such as anxiety attacks, or internal stressors such as
excess cortisol levels. Low heart rate variability reflects excessive sympathetic and/or inadequate
parasympathetic modulation of heart rate, and this is a strong predictor of mortality in patients
with CHD. Higher heart rate variability typically means that the body has a strong ability to tolerate
stress or is strongly recovering from prior accumulated stress. At rest, a high HRV is generally
favorable and a low HRV is unfavorable. Various studies of both patients with stable CHD and
patients that had recently had an acute coronary event have shown high heart rate variability to be
decreased in patients with depression than with patients not diagnosed with depression. This can
provide an overview of this conclusion and shows that HRV may account for a substantial part of
the risk associated with depression in CHD. What could be the cause of this variability in heart
rate?
Depression has been linked with various behavioral and biological irregularities that could
potentially explain the increase in risk of mortality in depressed patients with cardiac disease.
These risks can, but are not limited to a reduced adherence to treatment advice given by physicians,
an increase in prevalence of bad habits such as smoking, an increase in prevalence of diabetes, a
formation of dysfunction in platelets and coagulation processes, inflammatory processes, and
changes in autonomic nervous system function. Overall, all of these risk factors could potentially
contribute to the increased risk for cardiac morbidity and mortality in patients diagnosed with
depression. Autonomic nervous system dysfunction has shown on numerous occasions to be the
most dangerous. Excessive sympathetic or reduced parasympathetic nervous system activity in
patients diagnosed with CHD may lead to myocardial ischemia, ventricular tachycardia,
ventricular fibrillation, and even sudden cardiac death.
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Abnormal catecholamine levels, neurotransmitters that are released during stress, have been
shown to be associated with CHD. Multiple studies that have been performed dating back to the
1960s have shown that plasma and urinary catecholamine levels and resting heart rate levels to
be elevated in medically well psychiatric patients with major depression in comparison to
nondepressed controls. Studies of patients with CHD have also found elevated resting and 24hour HRs in depressed compared with nondepressed patients.

Figure 7: Potential mechanisms linking depression and coronary heart disease.25
Additional evidence of ANS dysfunction in depressed CHD patients has shown an increased HR
response to orthostatic challenge, increased QT interval variability that reflects abnormal
ventricular repolarization, an abnormal HR response to ventricular arrhythmias (turbulence), and
an increased incidence of ventricular tachycardia (HR over 100 bpm). All of these factors have
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shown to have been related to ANS dysfunction, and all are great predictors of mortality in cardiac
patients.
Depression is a common psychiatric disorder in patients with coronary heart disease
(CHD). Annually, 7% of Americans are diagnosed with major depression and the overall lifetime
prevalence of major depression in the United States is approximately 16%. Of all the patients
diagnosed with CHD, approximately 20% have major depression at any point in time. Also, about
20% suffer from minor depression as well. When a patient suffers any acute coronary event, there
is a 12 month period following it where up to 30% of patients may develop major depression.
However, the amount of minor depression during this 12-month period has not been reported
consistently, but is also estimated to be about 30%. Therefore, up to 60% of patients with an acute
coronary event experience symptom of depression within the 12 months following the event. Why
is this the case?
Ultimately, this research does not prove the true relationship between depression, CAD, and
mortality. However, these results do show that they are consistent with the idea that HRV and a
combination of measures of HR response to stimuli may account for a significant percentage of
depression’s relationship with mortality following a myocardial infarction.
Diabetes and Coronary Artery Disease
Diabetes mellitus is a disorder in which the body does not produce enough or respond normally
to insulin, causing blood sugar (glucose) levels to be abnormally high. Interestingly, diabetes has
been shown to have a prevalent link with coronary artery disease.26 Diabetes is treatable, but
even when glucose levels are regulated and under severe control it greatly increases the risk of
heart disease and stroke. The frequency of diabetes mellitus has reached enormous levels
worldwide, and its frequency is only rising. A patient discovering they are diagnosed with DM
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can lead to many things. The effects of a diagnosis of DM are as dangerous as a diagnosis of
coronary artery disease. Also, DM (especially type 2 DM), is associated with risk factors for
cardiovascular disease (CVD). There is a prevalence of 75% to 85% of hypertension, 70% to
80% for elevated LDL, and 60% to 70% for obesity amongst adults with DM. While the patients
undergo a glucose deficiency, CAD is the main cause of death in both type 1 and type 2 DM.
DM is correlated with approximately a 2 to 4-fold increased mortality risk from heart disease.
Also, in patients diagnosed with DM that are exposed to myocardial infarction, there is an
increased mortality and patients typically express an overall worse long-term prognosis with
CAD.
Coronary artery disease is the greatest determinant of the long-term prognosis among
patients with diabetes mellitus. Statins, a class of lipid-lowering medications that reduce illness
and mortality in those who are at high risk of cardiovascular disease, are effective in reducing
major coronary events, stroke, and the need for coronary revascularization. However, strict
control of a patient’s glycemic index, or a measure of how much a specific food raises a patient’s
blood glucose levels, for an average of 3.5 to 5 years has shown to not reduce cardiovascular
events. This begs the question, how can a disease that deals with glucose and insulin have such
drastic effects on the heart? Besides lifestyle habits that are common between CAD patients and
DM patients, the main physiological culprit that researchers can deduce is the bridge between
these two illnesses is hypoglycemia, the state of the body when blood glucose levels are lower
than normal.
Hypoglycemia and Mortality
Hypoglycemia is a substantial, independent cause of excess morbidity and mortality. There are
various mechanisms by which hypoglycemia might impact and or lead to cardiovascular events.
These events that potentially lead to death from cardiovascular disease include sympathoadrenal
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activation which is the release of chemical messengers to release a “fight or flight” response,
abnormal cardiac repolarization which is an abnormal ion level during relaxation of the myocardial
muscle, increased thrombogenesis which is blood clot formation, inflammation, and
vasoconstriction leading to less blood flow in the arteries during recognized or unrecognized
episodes of hypoglycemia.
While the relationship between hospitalized patients with acute myocardial infarction and
hypoglycemia is complex, there is a J-shaped curve relationship between glucose values and
specific outcomes, such as increased mortality. Within this relationship, hypoglycemia has
repeatedly shown to decrease myocardial blood flow reserve and increase experimental infarct
size. Therefore, this correlation provides sufficient evidence for caretakers to attempt to mitigate
the risk of hypoglycemia in patients with diabetes and CAD.
How do physicians treat hypoglycemia? In order to remove the potential risk of the drastic
cardiovascular events, physicians typically recommend to diabetic patients to keep blood glucose
higher than average compared to non-diabetic patients. This is done through constant measurement
of insulin levels, constant supplements of fast-acting carbohydrates such as fruits, or in drastic
measures some physicians prescribe glucagon, a hormone that raises blood glucose levels rapidly
(Figure 8).
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Figure 8: Management of Hypoglycemia in patients with acute coronary syndromes.26

Iatrogenic hypoglycemia, or hypoglycemia that occurs due to overuse of blood glucose lowering
medication, is the limiting factor in the glycemic management of DM. This condition typically
occurs due to the interplay of mild-to-moderate absolute or relative therapeutic hyperinsulinemia
and compromised physiological and behavioral defenses against falling plasma glucose
concentrations. Because of this, physicians must take great precautions when prescribing insulin
to diabetic patients as shown by the figure above.
How thin people get heart disease
As with any disease, there are certain cases that are unexplainable such as life-long smokers that
never develop lung cancer. Unfortunately, heart disease is not a stranger to these anomalies, and
the Behavioral Risk Factor Surveillance System database indicated in 2013 that the underweight
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population had a 19.7% greater risk of CAD than did the normal-weight. While genetics was
shown to play a role in determining risk factors for CAD, the majority of the concerns had to do
with lifestyle, so how do “healthy” people have such a substantial increased risk compared to
normal people? A genetic analysis performed on more than 75,000 people in the United Kingdom
showed that lean people (i.e. normal weight individuals) that had a specific genetic variant had a
higher chance of developing type 2 diabetes and heart disease even those individuals had a lower
body fat. The answer has to deal with the type of fat that people are storing.27
Most body mass indices detail how much body fat an individual might have, but it only accounts
for the adipose tissue that is deposited under the skin. Researchers have discovered that not just
the amount of fat individuals have, but the type of fat that is present in individuals is the key in
determining the risk that thin people have. Repeated instances have shown evidence that the fat
that is deposited under the skin does not contribute as much as previously believed to the
development of heart disease and diabetes. However, fat that is accumulated in organs, within
muscle, and fat that is buried within organs like the liver, for example, can have a greater risk of
developing these metabolic diseases. This shows that thin people, who might not have much visible
adipose fat, may be storing this “visceral fat” inside their body and organs.
What bodily process regulates where fat gets stored in individuals? Sadly, the process of
storing fat is largely genetic and gender based. Most women mainly tend to store subcutaneous fat
under the skin, but men are more predisposed to having fat deposited deeper within the tissues and
organs. As for the genetic reasons, researchers have identified one genetic variant out of more than
2.5 million candidate sites on the genome linked to body fat. This genetic variant has been shown
to predispose people to depositing visceral fat as opposed to the more benign subcutaneous fat.
This visceral fat has been shown to impair muscle and organ function within the body. The power
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of this genetic abnormality on metabolic factors such as cholesterol and triglyceride levels and
insulin resistance were very noticeable. Thinner people with low body fat, but who were carriers
of this version of the gene, constantly had elevated levels of blood cholesterol. These same
individuals were more likely to display resistance to processing insulin, one of the primary signs
of diabetes. However, most all of these individuals repeatedly displayed normal body mass index
or BMI readings.

Discussion
Overall, this section outlines the reasoning behind as to why Coronary Artery Disease is
not as easily diagnosable or treatable than other diseases. There are numerous anomalies that cause
it, numerous dangerous outcomes that can occur due to it, and other metabolic factors to take note
of after a patient is diagnosed with it. It is with great hope that one day there will be a way to
alleviate this versatility that currently exists in patients diagnosed with it.
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CHAPTER 5
CONCLUSION
Coronary Artery Disease is a volatile disease that has many causes and outcomes that can
occur throughout the body. Throughout the entirety of the literature, it is often commonly accepted
that while lifestyle is the major factor causing the disease, it is not uncommon for genetics to have
a severe impact as well. After studying the various impacts this disease can have on the body,
individuals, and the other important outcomes this disease can lead to, I have found that there is
significant cause for more extensive research, prevention plans, and patient care especially in
Mississippi. This correlation between eating habits, poor lifestyle, and inability to provide quality
access to care has been shown to be prevalent all throughout the South with Mississippi being a
prime example. Perhaps there is a commonality between these states and their authorities that can
explain in detail why this disease has become so prevalent to this day. Additionally, I propose that
the historical events that have contributed to the growth and development of Mississippians
resulted in a population that is more susceptible to develop coronary artery disease than any other
population during this time. The results of this paper highlight the importance of statistical analysis
of diseases in order to understand physiological differences in populations that live during this
time, and the caution that should be taken when these groups of individuals are going about life.
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